The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
But again your assuming that everyone who has ED and took part in the study has never touched their genitals and got an erection. I have never had the issue, but im sure if i did the first thing i would do would be to try and self stimulate before diagnosing myself or being clinically diagnosed with ED. I dont think a doctor would make that diagnosis on the basis that a man couldnt get it up on a single night without suggesting he tries a range of self stimulation. So if that didnt work and MED3000 did the trick, then we have a successful product that makes an impact to peoples lives and as such is marketable.
Your arguments make no sense what so ever and everything comes with a hyperlink that again is completely irrelevent. Adding a hyperlink does not give merit to the words you put together. We can all add a hyperlink:
https://www.dictionary.com/browse/idiot
Booth, So your now admitting that the treatment does have an impact and has good enough results to improve ED enough to mask potentially other conditions. This is a little contradictory to your other 551 posts which state that the treatment is not effective and is only a placebo. However it appears 15 seconds of use and the gaining of a hard on will stop people from expecting diabetes.
You cant have it both ways, it appears you have got lost in your own tangled web of lies and dont quite know where you stand on this treatment.
Here he goes again...... MED3000 now kills people.... Booth do you really not have anything better to do than spreading your nonsense. Next you will be telling us that MED3000 caused the Black Death or Spanish Flu.
Costain picked up three packages. One was the enabling works contract at Euston, which was a JV between Costain and Skanska (CSJV), this has a value of about £300m. They also picked up the Euston tunnel approaches (Lot S1) and the Northolt Tunnels (S2) as part of SCS JV (Strabag, Costain, Skanska). Lot S1 has a value of £600m - £900m and Lot S2 has a value of £850m - £1.4Bn. Although these values were the original procurement numbers (as such have probably significantly increased in line with the recent overall project increase.
Long and short of it the recent backing of HS2 has provided significant strength to the companies order book.
jazz_01, Im not sure which area of the industry you operate but the Construction industry tends to sit at the lower end of Margins, typically 2-3%. In relation to a buy out I see this as highly unlikely. Costain were ranked the 11th largest construction company in the UK in 2018. If you look at those above, they are all having serious difficulties at present, for example Kier who's SP is in the toilet and could be looking at a rights issue. Interserve have recently gone through administration. Laing O'Rourke who have very little capital (even being refused credit for materials).
The only potentials are Balfour Beatty and Skanska, however this wouldn't make sense as they operate in the same sectors and hold similar frameworks, as such there is nothing in Costain that they would want to buy.
This isn't to say Costain are a bad company, they operate very well in a highly competitive industry and return good margins. They also have a solid balance sheet (which is rare in the top 20 UK construction companies). This was definitely oversold on the profit warning and has had its SP held down for a prolonged period now. The SP will sail back over 200 and probably settle around 230 ahead of further trading updates later in the year.
Slightly confused with the massive drop off in this sp... yes the company has just reported a lower turnover, but they are still sitting on gross profit margin figures of 27%, not to mention turnover of £50M in the first 9 months and a cash equivalent balance of £25M. The bad debt on the contract amounts to £5M.....if not paid.... but this still keeps the company in good profit. The sp certainly does not reflect the current status of the company. This should be sitting up around 17.25 .... big buy recommend here. Even with a cut in dividend you would still make 25% yield on the divi.
This share will bounce back, profit warning announced, although still expected to post an underlying profit of £380M-£420M for the year, which isn't bad considering the current market climate.
Dividend has hit the brokers accounts. Very good yield, and the company looks extremely strong for next year. Thoroughly recommend a strong buy.
Stock seems very slow despite good growth reports and a sustantial order book.
Is this lunchtime SP drop on the back of Goldmans target price reduction?
Annual Report seems quite good, still showing profit of 2bn down from 15bn, the august/September 15 commodities drop could see this turn red next year though. Still to much uncertainty in commodities market to know quite what to do with this share.
Where did you get that information from?